PRNewswire-PRWebJune 2, 2025
HepQuant Achieves ISO 13485 Certification to Support Scaling of HepQuant DuO™ to Global Clinical Trials
HepQuant, LLC, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is proud to announce ISO 13485 certification as its latest milestone in operational excellence. This internationally recognized certification is a significant achievement that underscores the company's commitment to the highest standards in quality management and regulatory compliance. This milestone enhances HepQuant's abilities to engage in larger, more impactful clinical studies to drive transformative advancements to improve liver health.
May 12, 2025
HepQuant Demonstrates New Advancements in Management of Patients with Acute Liver Failure Dependent on Extracorporeal Liver Cross-Circulation (ELC)
Simultaneous evaluation of Human and Porcine liver functions using 13C-Cholate quantification may aid in future management of patients with acute liver failure who are assisted by ELC systems while awaiting transplant.In The News
April 23, 2025
HepQuant Celebrates Lab Week 2025!
Our amazing lab team is the backbone of our company, powering innovation, precision, and progress every single day. Their dedication to science, quality, and patient impact makes everything we do possible. This week, we recognize and thank our lab professionals for their hard work behind the scenes—advancing liver disease diagnostics and helping improve lives. 🔬 Here’s to the problem solvers, data champions, and science heroes in the lab. We appreciate you today and every day!Events
September 12, 2025 - September 14, 2025Houston, TX